Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “JAK2 V617F”

10 trials

Showing 10 of 10 results

Testing effectiveness (Phase 2)Ended earlyNCT01038856
What this trial is testing

Trial of Erlotinib in Patients With JAK-2 V617F Positive Polycythemia Vera

Who this might be right for
Polycythemia Vera
University of Oklahoma 5
Large-scale testing (Phase 3)Looking for participantsNCT05198960
What this trial is testing

AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms

Who this might be right for
Polycythemia VeraEssential ThrombocythemiaPrefibrotic/Early Primary Myelofibrosis+2 more
University Hospital, Brest 1,308
Not applicableStudy completedNCT01352585
What this trial is testing

Exploratory Multi-centre Trial In Patients With ET Treated With XAGRID®

Who this might be right for
Essential Thrombocythemia (ET)
Shire 47
Early research (Phase 1)Study completedNCT01134120
What this trial is testing

A Study in Myeloproliferative Disorders

Who this might be right for
Myeloproliferative DisordersThrombocythemia, EssentialPolycythemia Vera+1 more
Eli Lilly and Company 80
Testing effectiveness (Phase 2)Study completedNCT00586651
What this trial is testing

Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis

Who this might be right for
Polycythemia VeraEssential Thrombocytosis
Cephalon 39
Testing effectiveness (Phase 2)Study completedNCT02311569
What this trial is testing

Sympathicomimetic Agonist in Patients With Myeloproliferative Neoplasms With JAK2-mutation

Who this might be right for
Myeloproliferative NeoplasmPrimary MyelofibrosisEssential Thrombocythemia+1 more
Swiss Cancer Institute 39
Testing effectiveness (Phase 2)UnknownNCT00668421
What this trial is testing

CEP-701 (Lestaurtinib) in Myelofibrosis

Who this might be right for
MyelofibrosisEssential ThrombocythemiaPolycythemia Vera
Ronald Hoffman 60
Early research (Phase 1)Not Yet RecruitingNCT07249840
What this trial is testing

Ropeginterferon for High Risk JAK2 Clonal Hematopoiesis

Who this might be right for
JAK2 Mutation
Brigham and Women's Hospital 12
Not applicableStudy completedNCT03828422
What this trial is testing

Arterial Function and Atherosclerosis in Essential Thrombocythemia

Who this might be right for
Atherosclerosis
University Medical Centre Ljubljana 82
Testing effectiveness (Phase 2)Study completedNCT00606307
What this trial is testing

Phase IIA Study of the HDAC Inhibitor ITF2357 in Patients With JAK-2 V617F Positive Chronic Myeloproliferative Diseases

Who this might be right for
Myeloproliferative Diseases
Italfarmaco 29

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation